Skip to main content

IRADIMED CORP

For the period ended Dec 31, 2025. Filed Mar 6, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 6, 2026

IRMD$86.94+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · Common Stock · ​ · Paid-in · ​ · Retained · ​ · Stockholders’
​ · ​ ​ ​ · ​ · ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Earnings · ​ ​ ​ · Equity
Balances, December 31, 2023​​12,660$1$28,161$43,258$71,420
Net income​​—​​—​​—​​19,234​​19,234
Dividends declared​​—​​—​​—​​(5,701)​​(5,701)
Stock-based compensation expense​​—​​—​​2,524​​—​​2,524
Net share settlement of restricted stock units​​40​​—​​(557)​​—​​(557)
Net share settlement of performance based stock units​​​7​​—​​(131)​​—​​(131)
Exercise of stock options​​3​​—​​30​​—​​30
Balances, December 31, 2024​​12,710$1$30,027$56,791$86,819
Net income​​—​​—​​—​​22,480​​22,480
Dividends declared​​—​​—​​—​​(15,040)​​(15,040)
Stock-based compensation expense​​—​​—​​2,919​​—​​2,919
Net share settlement of restricted stock units​​47​​—​​(1,429)​​—​​(1,429)
Net share settlement of performance based stock units​​​25​​—​​(1,131)​​—​​(1,131)
Balances, December 31, 2025​​12,782$1$30,386$64,231$94,618
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.